A phase II, open-label, multicenter clinical trial to assess the efficacy and safety of the PARP inhibitor, olaparib, alone in previously-treated patients with stage IV, measurable colorectal cancer, stratified by MSI status.
To assess if AZD2281 can effectively and safely treat advanced large bowel cancer. The primary goal of this clinical trial is to determine whether olaparib will have a beneficial effect on the patient's cancer by causing a response and increasing the time it takes for the cancer to progress
Tumor response as assessed by RECIST
AZD2281 is an investigational compound. This information is intended for potential clinical investigators and other interested physicians who may wish to enroll patients in clinical trials.
For more information, please contact:
Cancer Study Locator service, sponsored by AstraZeneca at 1-877-400-4656 or via e-mail at: astrazeneca@emergingmed.com
To find available investigator site details, go to: www.clinicaltrials.gov
Download PDF (PDF— 
244 KB)